BCD-178

Investigational biosimilar product
List of clinical studies

BCD-178 is a monoclonal antibody being developed as a biosimilar to Perjeta® (international nonproprietary name: pertuzumab).

A monoclonal antibody is a protein created by scientists in a laboratory, similar to the natural antibodies of the immune system, designed to bind to a specific target in the human body1.

BCD-178 is one of the drugs in BIOCAD’s clinical development program.

  1. Weiner LM, Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology. 2010;10(5):317–27.

​This section of the website contains information about an unauthorized investigational medicinal product for medical use.​